Want to see NTRA full AI Analyst Report?
NTRA Stock Chart & Stats
$261.99
-$0.15(-0.06%)
At close: 4:00 PM EDT
$261.99
-$0.15(-0.06%)
Day’s Range― - ―
52-Week Range$157.43 - $333.56
Previous CloseN/A
Volume87.41K
Average Volume (3M)1.44M
Market Cap
$46.86B
Enterprise Value$38.04K
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$238.49M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 11, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding144,144,170
10 Day Avg. Volume924,721
30 Day Avg. Volume1,435,349
Financial Highlights & Ratios
PEG Ratio230.60
Price to Book (P/B)18.29
Price to Sales (P/S)13.58
P/FCF Ratio287.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$335.29Price Target Upside27.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-1.36
Revenue Forecast (FY)$2.90B
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationNatera has shifted to positive operating and free cash flow, a durable structural improvement that funds operations, clinical trials, and commercialization without immediate reliance on capital markets. This strengthens financial flexibility and reduces dilution pressure while supporting multi-quarter investments.
Strong Revenue & Volume GrowthSustained double‑digit revenue growth and record test volumes indicate broadening clinical adoption across oncology, women's health, and transplant. Raised guidance reflects durable demand, offering lasting scale benefits (better absorption of fixed costs and leverage for margin improvement) over coming quarters.
Regulatory & Guideline WinsMultiple regulatory approvals and a Category 1 guideline materially lower commercialization friction: they expand reimbursement access and clinical trust across markets. These structural endorsements support sustained adoption, higher institutional uptake, and longer‑term pricing leverage.
Bears Say
Ongoing UnprofitabilityDespite revenue scale and margin progress, the business is still loss‑making at the operating level. Persistent negative operating margins mean the firm must convert top‑line growth into sustained operating earnings to deliver durable returns and to relieve reliance on external capital or sustained tight cost control.
Reimbursement Dependence For ASP UpsideMaterial further pricing and margin expansion depend on external coverage decisions and policy shifts. Such reimbursement outcomes are multi‑quarter structural risks: delays or narrower coverage would limit ASP growth and compress margins across oncology volumes despite clinical demand.
Large Near‑Term R&D InvestmentA sizable, ongoing $100M investment program into early cancer detection diverts cash and operating focus. While strategically important, trial and regulatory risk mean benefits may not materialize for multiple quarters, pressuring near‑term free cash flow growth and margin expansion during the pivotal FIND readout timeline.
NTRA FAQ
What was Natera Inc.’s price range in the past 12 months?
Natera Inc. lowest stock price was $157.43 and its highest was $333.56 in the past 12 months.
What is Natera Inc.’s market cap?
Natera Inc.’s market cap is $46.86B.
When is Natera Inc.’s upcoming earnings report date?
Natera Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 82 days.
How were Natera Inc.’s earnings last quarter?
Natera Inc. released its earnings results on Aug 06, 2026. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.494 by $0.024.
Is Natera Inc. overvalued?
According to Wall Street analysts Natera Inc.’s price is currently Undervalued.
Does Natera Inc. pay dividends?
Natera Inc. does not currently pay dividends.
What is Natera Inc.’s EPS estimate?
Natera Inc.’s EPS estimate is -0.22.
How many shares outstanding does Natera Inc. have?
Natera Inc. has 144,144,170 shares outstanding.
What happened to Natera Inc.’s price movement after its last earnings report?
Natera Inc. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.494. Following the earnings report the stock price went up 21.373%.
Which hedge fund is a major shareholder of Natera Inc.?
Currently, no hedge funds are holding shares in NTRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Natera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$335.29 (27.98% Upside)
$335.29 (27.98% Upside)
Blogger Sentiment
Bullish
NTRA Sentiment 60%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 450.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
51.25%
Trailing 12-Months
Company Description
Natera Inc.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
NTRA Company Deck
NTRA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and multiple high‑impact milestones (record volumes, robust revenue growth, major regulatory approvals, new guideline support, improved ASPs and margins, raised guidance, and a deep prospective clinical program). These positives are partially offset by near-term margin pressure from new product ramps, substantial investment in early cancer detection that depresses near-term profitability, reliance on future coverage actions for major ASP upside, and some one-time/variable SG&A items. Overall, the balance of evidence points to accelerating commercialization and durable long‑term opportunity despite expected short‑term investment and mix effects.View all NTRA earnings summariesNTRA Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$335.29
▲(27.98% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
2.99% Insiders
34.08% Mutual Funds
25.37% Other Institutional Investors
21.50% Public Companies and
Individual Investors











